Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome (Q33366172)

26 July 2017

title

Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome (English)

1 reference

hemolytic-uremic syndrome

26 July 2017

main subject

1 reference

1 reference

1 reference

Yassa SK

1

1 reference

26 July 2017

Blessios G

series ordinal

2

1 reference

26 July 2017

Marinides G

series ordinal

3

1 reference

26 July 2017

Venuto RC

series ordinal

4

1 reference

26 July 2017

publication date

1 June 2005

1 reference

26 July 2017

published in

Clinical Transplantation

1 reference

26 July 2017

volume

19

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

423-426

1 reference

Recurrence of haemolytic-uraemic syndrome in renal transplants: a single-centre report

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00334.X

An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00334.X

Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00334.X

von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00334.X

Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00334.X

Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00334.X

Rituximab therapy for refractory thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00334.X

Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00334.X

Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00334.X

Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00334.X

Hemolytic uremic syndrome: how do factor H mutants mediate endothelial damage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00334.X

Thrombotic Microangiopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00334.X

10.1111/J.1399-0012.2005.00334.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference